<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515602</url>
  </required_header>
  <id_info>
    <org_study_id>FOCUS</org_study_id>
    <secondary_id>SOC-4</secondary_id>
    <secondary_id>SGOG-OV6</secondary_id>
    <nct_id>NCT04515602</nct_id>
  </id_info>
  <brief_title>Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)</brief_title>
  <official_title>Stratified Evaluation and Prediction of Survival Benefit for PDS or NACT-IDS in Advanced Ovarian Cancer, A Randomized, Phase 3 Trial After the SUNNY Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai First Maternity and Infant Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to answer the fundamental question 'The Optimal Timing of&#xD;
      Surgery' in advanced ovarian cancer patients with different tumor burden, and to perform&#xD;
      translational study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Compare the efficacy and safety in patients with advanced ovarian cancer treated&#xD;
      with NACT-IDS versus PDS, among different tumor burden groups. Compare survival benefit of&#xD;
      PARPi therapy in patients treated with PDS or NACT-IDS.&#xD;
&#xD;
      OUTLINE: This is a randomized phase III multicenter study. Patients will receive upfront&#xD;
      maximal cytoreductive surgery followed by at least 6 cycles of adjuvant chemotherapy or 3&#xD;
      cycles of neoadjuvant chemotherapy followed by interval debulking surgery, and then at least&#xD;
      3 cycles of adjuvant chemotherapy, and maintenance therapy of PARP inhibitor for patients&#xD;
      with gBRCA/sBRCA mutation who had a complete or partial clinical response after&#xD;
      platinum-based chemotherapy. Patients are followed every 3 months within the first 5 years,&#xD;
      and then every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 410 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Participants will be followed for at least 5 years after randomization</time_frame>
    <description>Time from randomization to the date of death from any cause or date of last contact</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Participants will be followed for at least 2 years after randomization</time_frame>
    <description>Time from randomization to the date of first progressive disease or death, whichever occurs first or date of last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative complications</measure>
    <time_frame>Participants will be followed up to 3 months after randomization</time_frame>
    <description>The surgical complications will be evaluated at 30-day, 60-day, 90-day after upfront cytoreductive surgery or interval debulking surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>Participants will be followed for at least 12 months or death after randomization, whichever came first</time_frame>
    <description>Quality of life (Qol) as measured by QOQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>Participants will be followed for at least 12 months or death after randomization, whichever came first</time_frame>
    <description>Quality of life (Qol) as measured by FACT-O</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulating treatment-free survival</measure>
    <time_frame>Participants will be followed for at least 5 years or death after randomization, whichever came first</time_frame>
    <description>The overall survival time minus the total treatment time of surgery and chemotherapy after randomization, regardless of the targeted therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent anticancer therapy</measure>
    <time_frame>Participants will be followed for at least 2 years or death after randomization, whichever came first</time_frame>
    <description>Time from the date of randomization to the starting date of the first subsequent anticancer therapy or death, whichever occurs first or date of last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to secondary subsequent anticancer therapy</measure>
    <time_frame>Participants will be followed for at least 5 years or death after randomization, whichever came first</time_frame>
    <description>Time from the date of randomization to the starting date of the second subsequent anticancer therapy or death, whichever occurs first or date of last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival 2</measure>
    <time_frame>Participants will be followed for at least 5 years or death after randomization, whichever came first</time_frame>
    <description>Time from randomization to second progressive disease or death, which occurs first or date of last contact</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Part 1 Arm I (low/medium tumor burden)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm II (low/medium tumor burden)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm I (high tumor burden)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm II (high tumor burden)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary debulking surgery</intervention_name>
    <description>Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.</description>
    <arm_group_label>Part 1 Arm I (low/medium tumor burden)</arm_group_label>
    <arm_group_label>Part 2 Arm I (high tumor burden)</arm_group_label>
    <other_name>PDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy</intervention_name>
    <description>3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.</description>
    <arm_group_label>Part 1 Arm II (low/medium tumor burden)</arm_group_label>
    <arm_group_label>Part 2 Arm II (high tumor burden)</arm_group_label>
    <other_name>Neoadjuvant chemotherapy followed by interval debulking surgery, NACT-IDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PARPi</intervention_name>
    <description>For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.</description>
    <arm_group_label>Part 1 Arm I (low/medium tumor burden)</arm_group_label>
    <arm_group_label>Part 1 Arm II (low/medium tumor burden)</arm_group_label>
    <arm_group_label>Part 2 Arm I (high tumor burden)</arm_group_label>
    <arm_group_label>Part 2 Arm II (high tumor burden)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For Part 1:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Females aged ≥ 18 years.&#xD;
&#xD;
          2. Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube&#xD;
             cancer or primary peritoneal carcinoma (diagnosis by biopsy or core needle biopsy*,&#xD;
             laparoscopic biopsy is not recommended). * If core needle biopsy could not be&#xD;
             performed, patients should satisfy the following conditions:&#xD;
&#xD;
               1. the patient has a pelvic mass, and&#xD;
&#xD;
               2. omental cake or other metastasis larger than 2 cm in the upper abdomen, or&#xD;
                  pathologic confirmed extra-abdominal metastasis (FIGO IV), and&#xD;
&#xD;
               3. preoperative CA125/CEA ratio &gt; 25. If CA125/CEA ratio ≤ 25, imaging or endoscopy&#xD;
                  is obligatory to exclude a primary gastric, colon, or breast carcinoma.&#xD;
&#xD;
          3. cPCI score ≤ 8.&#xD;
&#xD;
          4. Performance status (ECOG 0-2).&#xD;
&#xD;
          5. Good ASA score (1/2).&#xD;
&#xD;
          6. Adequate bone marrow, renal and hepatic function to receive chemotherapy and&#xD;
             subsequent surgery:&#xD;
&#xD;
               1. white blood cells &gt;3,000/µL, absolute neutrophil count ≥1,500/µL, platelets&#xD;
                  ≥100,000/µL, hemoglobin ≥9 g/dL,&#xD;
&#xD;
               2. serum creatinine &lt;1.25 x upper normal limit (UNL) or creatinine clearance ≥60&#xD;
                  mL/min according to Cockroft-Gault formula or to local lab measurement,&#xD;
&#xD;
               3. serum bilirubin &lt;1.25 x UNL, AST(SGOT) and ALT(SGPT) &lt;2.5 x UNL.&#xD;
&#xD;
          7. Comply with the study protocol and follow-up.&#xD;
&#xD;
          8. Patients who have given their written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-epithelial ovarian malignancies and borderline tumors.&#xD;
&#xD;
          2. Low grade ovarian cancer.&#xD;
&#xD;
          3. Mucinous ovarian cancer.&#xD;
&#xD;
          4. cPCI score &gt; 8.&#xD;
&#xD;
          5. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ&#xD;
             or breast carcinoma (without any signs of relapse or activity).&#xD;
&#xD;
          6. Any other concurrent medical conditions contraindicating surgery or chemotherapy that&#xD;
             could compromise the adherence to the protocol.&#xD;
&#xD;
          7. Other conditions, such as religious, psychological and other factors, that could&#xD;
             interfere with provision of informed consent, compliance to study procedures, or&#xD;
             follow-up.&#xD;
&#xD;
        For Part 2:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Females aged ≥ 18 years, and &lt; 70 years.&#xD;
&#xD;
          2. Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube&#xD;
             cancer or primary peritoneal carcinoma.&#xD;
&#xD;
          3. cPCI score ≥ 10.&#xD;
&#xD;
          4. For FIGO IVB patients, abdominal lesions should be confined to one lobe of liver&#xD;
             parenchyma metastasis or splenic metastasis. All extra-abdominal metastases should be&#xD;
             resectable, such as inguinal lymph nodes, solitary supraclavicular, retrocrural or&#xD;
             paracardial nodes.&#xD;
&#xD;
          5. Good performance status (ECOG 0-1).&#xD;
&#xD;
          6. Good ASA score (1/2).&#xD;
&#xD;
          7. Adequate bone marrow, renal and hepatic function to receive chemotherapy and&#xD;
             subsequent surgery.&#xD;
&#xD;
          8. Comply with the study protocol and follow-up.&#xD;
&#xD;
          9. Patients who have given their written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-epithelial ovarian malignancies and borderline tumors.&#xD;
&#xD;
          2. Low grade ovarian cancer.&#xD;
&#xD;
          3. Mucinous ovarian cancer.&#xD;
&#xD;
          4. Clear cell carcinoma.&#xD;
&#xD;
          5. cPCI score &lt; 8.&#xD;
&#xD;
          6. Lung metastasis, diffused pleural metastasis, bone metastasis, metastasis of&#xD;
             mediastinal lymph node, internal mammary node, or multiple extra-peritoneal lymph&#xD;
             nodes.&#xD;
&#xD;
          7. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ&#xD;
             or breast carcinoma (without any signs of relapse or activity).&#xD;
&#xD;
          8. Any other concurrent medical conditions contraindicating surgery or chemotherapy that&#xD;
             could compromise the adherence to the protocol.&#xD;
&#xD;
          9. Other conditions, such as religious, psychological and other factors, that could&#xD;
             interfere with provision of informed consent, compliance to study procedures, or&#xD;
             follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lina Shen, MD</last_name>
    <phone>86 21 64041990</phone>
    <email>shen.lina@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tingyu Luan</last_name>
    <phone>86 21 64041990</phone>
    <email>luan.yuting@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetrics &amp; Gynecology Hospital of Fundan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Jiang, MD, PhD</last_name>
      <phone>86 21 33189900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai First Maternity and Infant Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoqing Guo, MD, PhD</last_name>
      <phone>86 21 20261000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University School of Medicine Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xipeng Wang, MD, PhD</last_name>
      <phone>86 21 25078999</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

